Clinical Trials Logo

Clinical Trial Summary

Intrastent restenosis is a common complication after intracranial and extracranial arterial stenting and an important cause of recurrent ischemic stroke. Studies have shown that Tongxinluo capsule can protect the injured inner cells, reduce inflammation, inhibit the proliferation and migration of smooth muscle cells, inhibit the proliferation of plaque and nourish blood vessels, and resist arteriosclerosis. This study was a multicenter prospective randomized controlled clinical trial. Participants with intracranial and extracranial atherosclerotic stenosis who successfully underwent arterial stenting were included in the study, and were divided into Tongxinluo test group and control group. Clinical and related auxiliary examination data were collected at each follow-up point. To explore the effectiveness and potential mechanism of Tongxinluo capsule in preventing and treating restenosis after intracranial and external arterial stenting, and to provide reference for expanding clinical use of traditional Chinese medicine.


Clinical Trial Description

Study participants aged 45-80 years who met the criteria for symptomatic or asymptomatic cerebral artery stenosis and successfully underwent cerebrovascular stenting were randomly divided into test group and control group. On the basis of routine oral treatment ,participants in experimental group were given Tongxinluo capsule. The control group received routine oral treatment. The routine follow-up sites were 1, 3, 6 and 12 months, and clinical data and blood were collected at the initial diagnosis and each follow-up site. SPSS software was used to analyze whether Tongxinluo capsule could reduce restenosis after intracranial and extracranial arterial stenting. During the follow-up, the adverse reactions such as bleeding and gastrointestinal tract were observed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06112028
Study type Interventional
Source Qianfoshan Hospital
Contact
Status Not yet recruiting
Phase Phase 4
Start date October 2023
Completion date November 2026

See also
  Status Clinical Trial Phase
Completed NCT05591365 - Exercise Training in Coronary Artery Disease Patients After Stenting N/A
Completed NCT05315193 - Effect of Exercise Training in Coronary Artery Disease Patients After Stenting N/A
Active, not recruiting NCT03097679 - Self-expanding Nitinol Stents of High vs. Low Chronic Outward Force in De-novo Femoropopliteal Occlusive Arterial Lesions N/A
Recruiting NCT05346068 - The Value of IVL Compared To OPN Non-Compliant Balloons for Treatment of RefractorY Coronary Lesions (VICTORY) Trial N/A
Active, not recruiting NCT03349385 - Registry of Secondary Revascularization
Recruiting NCT04325867 - Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19 N/A
Recruiting NCT05244629 - Copenhagen Mesenteric Stent Study - A Randomized Trial of Stent Versus Covered Stent Treatment for Chronic Mesenteric Ischemia N/A
Completed NCT03544294 - veRy Thin Stents for Patients With Left mAIn or bifurcatioN in Real Life: the RAIN a Multicenter Study
Active, not recruiting NCT05217459 - The Efficacy and Safety of Intracranial Self-expanding DES in Symptomatic Intracranial Atherosclerotic Disease N/A
Recruiting NCT05205148 - Ultrathin DES in Complex PCI Scenarios: the ULTRA a Multicenter Study
Not yet recruiting NCT03375528 - Matrix Metalloproteinases Expression in the Neointimal Hyperplasia Induced by Drug Eluting Stent (DES) Implantation N/A
Completed NCT06276114 - IVL vs ELCA for Stent Underexpantsion (IVL-ELCA DRAGON)